PUBLIC COMPANY
save$AGENAGENUS INC
$AGENLexington, MA, USupdated 2mo ago
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
community read0 votes
pipeline
6
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
3Phase 13Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
- phase1Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
- phase2RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
- phase2A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
- phase2A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
- phase1A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
- phase2A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- phase2A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Apr 17, 26grantARMEN GARO H · See Remarks3,403 sh
🐶 Hiring Signal
News
- Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand dealPlus news about Amgen, Novartis, Boomray, Merck's Winrevair, Lexeo and Mantle. Ionis and Otsuka tout Phase 3 win in specific type of ALS: Ionis said its Otsuka-partnered drug candidate, ulefnersen,endpoints · 12d ago
- ARPA-H picks UpDoc, Tempus and Atman to build AI tools for heart diseaseUpDoc, Tempus AI and Atman Health will participate in a new program that aims to build FDA-authorized agentic AI tools to care for people with heart disease, the federal government announced Wednes…endpoints · 25d ago
- Post-Hoc Live: MAHA, the new Trump CDC pick and RFK's vaccine agendaMAHA’s sway over HHS could face a fresh test now that President Trump has a new pick for CDC director: Erica Schwartz, a former deputy surgeon general. The position has been empty ...endpoints · 5mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that